(Q51549131)

6 April 2018

title

Challenges and opportunities in childhood cancer drug development. (English)

1 reference

6 April 2018

1 reference

Robin E Norris

1

1 reference

6 April 2018

Peter C Adamson

series ordinal

2

1 reference

6 April 2018

language of work or name

English

0 references

publication date

11 October 2012

1 reference

6 April 2018

published in

Nature Reviews Cancer

1 reference

6 April 2018

volume

12

1 reference

6 April 2018

page(s)

776-782

1 reference

6 April 2018

issue

11

1 reference

6 April 2018

https://scigraph.springernature.com/pub.10.1038/nrc3370

exact match

0 references

cites work

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

31 March 2020

Cancer statistics, 2009

1 reference

New approaches to drug development in pediatric oncology

31 March 2020

1 reference

Long-term follow-up of childhood cancer survivors: future directions for clinical care and research

31 March 2020

1 reference

Chronic health conditions in adult survivors of childhood cancer

31 March 2020

1 reference

Overcoming implementation challenges of personalized cancer therapy

31 March 2020

1 reference

Implications of genetic heterogeneity in cancer

31 March 2020

1 reference

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy

31 March 2020

1 reference

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

31 March 2020

1 reference

Treating childhood acute lymphoblastic leukemia without cranial irradiation

31 March 2020

1 reference

L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y

31 March 2020

1 reference

Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood

31 March 2020

1 reference

Drug dosage and remission duration in childhood lymphocytic leukemia

31 March 2020

1 reference

The importance of dose intensity in chemotherapy of metastatic breast cancer

31 March 2020

1 reference

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

31 March 2020

1 reference

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma

31 March 2020

1 reference

Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features

31 March 2020

1 reference

The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively

31 March 2020

1 reference

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

31 March 2020

1 reference

Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study

31 March 2020

1 reference

Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study

31 March 2020

1 reference

Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas

31 March 2020

1 reference

Outcomes for children and adolescents with cancer: challenges for the twenty-first century

31 March 2020

1 reference

Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma

31 March 2020

1 reference

Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia

31 March 2020

1 reference

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease

31 March 2020

1 reference

Long-term cause-specific mortality among survivors of childhood cancer

31 March 2020

1 reference

A novel retinoblastoma therapy from genomic and epigenetic analyses

31 March 2020

1 reference

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

31 March 2020

1 reference

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

31 March 2020

1 reference

Treatment of Acute Leukemia

31 March 2020

1 reference

Developmental therapeutics program at the NCI: molecular target and drug discovery process

31 March 2020

1 reference

Practices and pitfalls of mouse cancer models in drug discovery.

31 March 2020

1 reference

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

31 March 2020

1 reference

Not just small adults: the metaphors of paediatrics

31 March 2020

1 reference

Developmental pharmacology--drug disposition, action, and therapy in infants and children

31 March 2020

1 reference

Pharmacokinetics of anticancer drugs in children

31 March 2020

1 reference

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia

31 March 2020

1 reference

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia

31 March 2020

1 reference

Using germline genomics to individualize pediatric cancer treatments

31 March 2020

1 reference

Improving outcomes for high-risk ALL: translating new discoveries into clinical care

31 March 2020

1 reference

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia

31 March 2020

1 reference

JAK mutations in high-risk childhood acute lymphoblastic leukemia

31 March 2020

1 reference

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

31 March 2020

1 reference

New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.

31 March 2020

1 reference

Pharmacokinetics in the newborn

31 March 2020

1 reference

The Effect of Age on Drug Metabolism

31 March 2020

1 reference

Nine years' experience with "total therapy" of childhood acute lymphocytic leukemia

31 March 2020

1 reference

12 December 2020

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

1 reference

12 December 2020

The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

1 reference

12 December 2020

The importance of pharmacokinetic limited sampling models for childhood cancer drug development

1 reference

12 December 2020

Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.

1 reference

12 December 2020

Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice

1 reference

12 December 2020

EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study

1 reference

12 December 2020

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Renal physiology Part 1: Structure and function.

1 reference

12 December 2020

A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3370

1 reference

6 April 2018

PubMed ID

23051845

1 reference

6 April 2018